 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...4849505152535455565758...123124» |
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date: Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. (clinicaltrials.gov) - Sep 27, 2022
P1/2, N=27, Not yet recruiting, Sponsor: National Taiwan University Hospital
Trial completion date: Dec 2025 --> Sep 2026 | Initiation date: Mar 2022 --> Oct 2022 | Trial primary completion date: Dec 2025 --> Sep 2026
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of #lenvatinib / #pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma. #RCC #kcsm | @ChungHanLee3 @MSKCancerCenter https://t.co/6wCmIRf7oV (Twitter) - Sep 26, 2022
- |||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Sep 26, 2022
P3, N=554, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2025 --> Sep 2026 | Initiation date: Mar 2022 --> Oct 2022 | Trial primary completion date: Dec 2025 --> Sep 2026 Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma. (Pubmed Central) - Sep 24, 2022
As a potentially valuable prognostic marker, RAB11A is a promising therapeutic target for LSCC. Evaluation of RAB11A may be useful for identification of LSCC in patients whose cancer is refractory to FGFR inhibitors.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The Beneficial Impact of MAFLD on Lenvatinib Treatment in Patients with Non-viral Hepatocellular Carcinoma. (Pubmed Central) - Sep 24, 2022
Moreover, the better OS of the MAFLD group was more pronounced in patients with non-viral HCC. Lenvatinib may be a suitable agent for patients with non-viral HCC and MAFLD.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Dr. Matthew Taylor @ChilesResearch @providence presenting remarkable responses to Lenvatinib + pembro in both Differentiated Thyroid Carcinoma Anaplastic Thyroid Carcinoma at the 5th New Horizons meeting. (Twitter) - Sep 23, 2022
- || Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P1/2 data, Journal: A Single-Arm Phase Ib/II Study of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. (Pubmed Central) - Sep 23, 2022
P1/2
Lenvatinib may be a suitable agent for patients with non-viral HCC and MAFLD. Lenvatinib plus eribulin has a manageable safety profile and exhibits promising efficacy for treating advanced LMS and LPS.
- ||||| everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Highlight Article: Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial https://t.co/4R3YxKQq4O @montypal @docjavip @DrDanielHeng (Twitter) - Sep 23, 2022
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
An oncologist explains his dosing strategies for #lenvatinib in advanced clear cell #RCC, with reference to the design of the KEYNOTE-426 trial. #kcsm | @MosheOrnsteinMD @ClevelandClinic @fredhutch @MDAndersonNews https://t.co/DE0G4FKP0j (Twitter) - Sep 22, 2022
- ||| Journal, Adverse events, Combination therapy: Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. (Pubmed Central) - Sep 22, 2022
Lenvatinib plus eribulin has a manageable safety profile and exhibits promising efficacy for treating advanced LMS and LPS. Patients with aRCC treated with first-line nivolumab-based therapies had lower grade 3/4 all-cause and treatment-related AE costs than pembrolizumab-based therapies, suggesting a more favorable cost-benefit profile.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Hans Hammers, MD, considers the role of lenvatinib plus pembrolizumab in the first-line treatment setting of advanced clear cell RCC. #rcc #kcsm | @brian_rini @montypal @HHammersMD @VUMChealth @cityofhope @UTSWHospitalMed https://t.co/eS5PBWsbJN (Twitter) - Sep 21, 2022
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. (Pubmed Central) - Sep 21, 2022
The most common TRAEs were neutropenia (50.8%), abdominal pain (45.9%), and aspartate aminotransferase increase (39.3%). Hepatic arterial infusion chemotherapy combined with PD-1 antibody and lenvatinib is effective in the treatment of advanced HCC, and the TRAEs are generally controllable.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition, IO biomarker: Sex differences in hepatocellular carcinoma indicated BEX4 as a potential target to improve efficacy of lenvatinib plus immune checkpoint inhibitors. (Pubmed Central) - Sep 21, 2022
Distinct biological processes were involved in sex-biased tumorigenesis of HCC. BEX4 can be targeted to improve the efficacy of lenvatinib plus immune checkpoint inhibitors.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial suspension: Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 21, 2022
P2, N=38, Suspended, Sponsor: Floor Backes
BEX4 can be targeted to improve the efficacy of lenvatinib plus immune checkpoint inhibitors. Recruiting --> Suspended
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Sep 21, 2022
P2, N=50, Enrolling by invitation, Sponsor: The Methodist Hospital Research Institute
Recruiting --> Suspended Not yet recruiting --> Enrolling by invitation | Trial completion date: Mar 2027 --> Dec 2027 | Initiation date: Dec 2021 --> Jun 2022 | Trial primary completion date: Sep 2026 --> Jun 2026
- ||| P3 data, Journal: Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. (Pubmed Central) - Sep 21, 2022
Atezolizumab plus bevacizumab was not statistically superior to durvalumab plus tremelimumab (HR 0·74; 95% CI 0·52-1·06) and sintilimab plus IBI305 (HR 1·02; 95% CI 0·67-1·55) in reducing the risk of death. Efficacy was associated with a higher risk of grade 3 adverse events.
- || Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Retrospective data, Clinical Trial,Phase II, Journal: Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. (Pubmed Central) - Sep 21, 2022
Lenvatinib, toripalimab and FOLFOX-HAIC showed safe and encouraging antitumour activity for advanced HCC with high-risk features. The levels of CCL28 and BTC might be the predictive biomarkers for the triple combination therapy.
- Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
LITESPARK-011: a randomized, phase 3 study of belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 therapy in patients with advanced renal cell carcinoma (Poster Hall, Board F4) - Sep 21, 2022 - Abstract #IKCS2022IKCS_140;
P3
Primary end points are PFS per RECIST v1.1 by blinded independent central review (BICR) and OS; secondary end points include ORR and DOR per RECIST v1.1 by BICR and safety and tolerability. LITESPARK-011 is recruiting patients in Asia, Australia, Europe, North America, and South America.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo) (Poster Hall, Board F3) - Sep 21, 2022 - Abstract #IKCS2022IKCS_139;
P2
PFS will be monitored using Bayesian optimal phase 2 design, and an interim analysis will be performed at 50 patients. The study has enrolled 8 patients to date at 1 US site and will open at 2 additional US sites by February 2023.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study (Poster Hall, Board D4) - Sep 21, 2022 - Abstract #IKCS2022IKCS_124;
Findings remained consistent after accounting for subsequent therapies, as evidenced by prolonged PFS2 and adjusted OS. Results further support lenvatinib + pembrolizumab as a standard of care in 1L aRCC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study (Poster Hall, Board C7) - Sep 21, 2022 - Abstract #IKCS2022IKCS_119;
A large proportion of patients treated with lenvatinib + pembrolizumab completed 2 years of pembrolizumab and continued with lenvatinib monotherapy with ongoing clinical benefit. The results further support lenvatinib + pembrolizumab as a standard of care in 1L aRCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Successful dose escalation of lenvatinib for thyroid cancer after disease progression. (Pubmed Central) - Sep 20, 2022
Drug holidays may be a key for successfully controlling AEs with DE. DE can be useful for controlling progressive disease with increasing Tg levels.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism. (Pubmed Central) - Sep 20, 2022
Though hypocalcaemia has been described as potential side effect of MKI treatment, this is the first report of a lenvatinib-induced primary hypoparathyroidism, in a patient with a documented normal parathyroid function after surgery. The periodical assessment of calcium-phosphorus metabolism is thus warranted to prevent this potentially lethal side effect, in both post-surgical hypoparathyroid and euparathyroid patients.
- | Bavencio (avelumab) / EMD Serono, Pfizer, Talzenna (talazoparib) / Pfizer
Journal, Mismatch repair, Tumor Mutational Burden, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. (Pubmed Central) - Sep 20, 2022
P2
Immunogenomic profiling provided insights that may inform ongoing and future studies of polyadenosine diphosphate-ribose polymerase and PD-L1 inhibitor combinations in endometrial cancer. ClinicalTrials.gov Identifier: NCT02912572.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) - Sep 20, 2022
Mechanistically, METTL1 promoted translation of EGFR pathway genes to trigger drug resistance. This work reveals the important role of METTL1-mediated m7G tRNA modification in promoting lenvatinib resistance and provides a promising prediction marker and intervention target for resistance.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The impact of lenvatinib on tumor blood vessel shrinkage of hepatocellular carcinoma during treatment: an imaging-based analysis. (Pubmed Central) - Sep 20, 2022
The shrinkage of TBV may be regarded as a process of normalization of TBVs. The shrinkage of tumor blood vessels in imaging analysis may be associated with improved prognosis; however, additional studies are still required.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data: 🔥Is response associated with OS in #HCC❓ 👉Our post-hoc analysis of REFELCT @JHepatology https://t.co/xiub7jQvN5 ✅mOS twice as long in responders vs non-responders 👇PR vs SD vs PD 🔥Lenvatinib valid option in 1st line ->LEAP-02 @EASLedu #LiverTwitter @myESMO @OncoAlert (Twitter) - Sep 20, 2022
- ||| Enrollment change, Trial completion date, Trial primary completion date: The Drug Rediscovery Protocol (DRUP Trial) (clinicaltrials.gov) - Sep 19, 2022
P2, N=1550, Recruiting, Sponsor: The Netherlands Cancer Institute
The shrinkage of tumor blood vessels in imaging analysis may be associated with improved prognosis; however, additional studies are still required. N=950 --> 1550 | Trial completion date: Dec 2022 --> Dec 2027 | Trial primary completion date: Aug 2022 --> Sep 2027
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (clinicaltrials.gov) - Sep 19, 2022
P2, N=44, Not yet recruiting, Sponsor: Melanoma Institute Australia
- | lenvatinib / Generic mfg.
Preclinical, Journal, Combination therapy: Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model. (Pubmed Central) - Sep 18, 2022
Our synergistic treatment effects by CTLI suggested its effectiveness for RAI-avid thyroid cancer, which retains NIS function. This potential combination therapy suggests a powerful and tolerable new therapeutic strategy for advanced thyroid cancer.
- || Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
PK/PD data, Preclinical, Journal: Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats. (Pubmed Central) - Sep 18, 2022
Canagliflozin caused a significant increase in AUC and C of lenvatinib by 28.9% and 36.2%, respectively, and a significant decrease in V and CL of lenvatinib by 52.9% and 22.7%, respectively. In conclusion, drug interactions exist between canagliflozin and sorafenib or lenvatinib, and these findings provide a reference for the use of these drugs in patients with HCC and T2DM.
- || Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
It is intriguing that PFS est at 2 yr with Len-pembro is ~45% only while with axi-pembro not reached. (Twitter) - Sep 16, 2022
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Treatment patterns, clinical outcomes, and costs following the approval of new systemic therapy medications for hepatocellular carcinoma. (Available On Demand; Poster Bd #: F1) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_470;
However, there was no associated change in clinical outcomes such as survival or serious infections, providing additional real-world evidence of marginal improvement, if any. Pharmacy costs decreased in the post-approval group, which may reflect a shift from oral sorafenib to newer injectable systemic therapies.
- ||||| Review: Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib https://t.co/7pmk12F9f8 #ESMO22 #kcsm #kidneycancer #RCC @DanaFarber @DrChoueiri @HarvardMed @GustaveRoussy @AlbigesL (Twitter) - Sep 15, 2022
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma. (Pubmed Central) - Sep 14, 2022
We were able to resume and continue ATZ + BEV without HPD, which was effective for HCC. We considered that DEB-TACE is an option for treating HPD.
- || Retrospective data, Review: Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis. (Pubmed Central) - Sep 14, 2022
A total of 12 eligible RCTs involved 1,959 patients and 13 treatments: apatinib, cabozantinib, anlotinib, nintedanib, lenvatinib, lenvatinib with low dose (LD), sorafenib, sorafenib plus everolimus, donafenib (200 mg), donafenib (300 mg), pazopanib (continuous), pazopanib (intermittent), and vandetanib...Patients who received lenvatinib or apatinib also had more grade 3 or higher adverse events. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=302249], identifier [CRD42022302249].
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Real-world evidence: Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients. (Pubmed Central) - Sep 14, 2022
The combination of anti-PD-1 antibodies and lenvatinib may benefit patients with unresectable HCC who progressed on lenvatinib. This study provides a real-world data and treatment choice for patients progressed with lenvatinib.
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with a combination of pembrolizumab and lenvatinib in the frontline treatment of non–clear cell renal cell carcinoma. #kicsm #ESMO22 | @myESMO @AlbigesL https://t.co/8UszJ2T0jb (Twitter) - Sep 14, 2022
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical, Interview: "The most recent change has been the use of #lenvatinib and #pembrolizumab for #MMR-proficient #tumors in the second-line setting." Today's #WednesdayWisdom comes from an #OncData interview with Ritu Salani (@RSalaniMD), MD, @UCLAHealth. Read here! https://t.co/HA4y5sFbPs (Twitter) - Sep 14, 2022
- | lenvatinib / Generic mfg.
Journal: Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. (Pubmed Central) - Sep 14, 2022
The results indicate that signal transduction via the EGFR pathway may be involved in the development of lenvatinib resistance in thyroid cancer cells. The inhibition of the EGFR pathway simultaneously by an EGFR inhibitor may have therapeutic potential for overcoming lenvatinib resistance in thyroid cancer.
- | lenvatinib / Generic mfg.
Journal: S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression. (Pubmed Central) - Sep 14, 2022
In addition, we found that a high concentration of Lenvatinib significantly downregulated the expression of S1PR1 and obviously enhanced S1PR1 knockdown-mediated angiogenesis inhibition, indicating that S1PR1 may be a target by which Lenvatinib combats angiogenesis in HCC. Thus, S1PR1 may be an important target for suppressing angiogenesis in HCC, and inhibiting S1PR1 is a promising approach to antitumor therapy in HCC.
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Pembrolizumab/lenvatinib combo shows promise in frontline nccRCC https://t.co/opiQSY0Yqc #ESMO22 #urology #urologist @AlbigesL (Twitter) - Sep 13, 2022
- | lenvatinib / Generic mfg.
Retrospective data, Journal: Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study. (Pubmed Central) - Sep 13, 2022
Lenvatinib plus PD-1 blockades demonstrated promising anticancer activity and acceptable toxicity for patients with unresectable HCC. And the conclusion should be validated in prospective clinical trials subsequently.
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
The #OncoAlertTopTweet 🚨Day4⃣ #ESMO22 #EONS15 Tweet: OncoAlert Colleague @DrChoueiri 🇺🇸 KEYNOTE B61 Revolutionary as always! @AlbigesL Great response for #nccRCC under PEMBRO+LEN Best, @weoncologists (Twitter) - Sep 12, 2022
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: Did not make it to #Paris for @myESMO? More on #keynote 775: #lenvatinib & #pembrolizumab for #endometrialcancer from @OncLive. #gyncsm #clinicaltrial #gcam #clinicaltrial #ESMO22 @EisaiGlobalOnc @Merck (Twitter) - Sep 12, 2022
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Potential approach to overcome checkpoint inhibitor resistance in a long-term survivor patient with recurrent endometrial carcinoma (ePoster kiosks (Exhibition area)) - Sep 12, 2022 - Abstract #ESGO2022ESGO_1072;
The combination of checkpoint inhibitor and a tyrosine kinase inhibitor is a potential approach to overcome checkpoint inhibitor resistance. Further clinical trials are warranted.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg., Sutent (sunitinib) / Pfizer
Clinical: Updated efficacy of lenvatinib + pembrolizumab vs sunitinib in patients with advanced #RenalCellCarcinoma in the #Clear study. Presentation by @CPRT65 @unibait. #ESMO22 written coverage by @WallisCJD @UofT > https://t.co/OCbpLe8SzJ @myESMO (Twitter) - Sep 12, 2022
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: @AlbigesL gives a wonderful talk @myESMO #ESMO22 in nccRCC with pembro/lenvatinib with about half of pts responding! Waterfall plot impressive! Toxicity needs attention. Chromophobe remains a highly unmet need! @OncoAlert @urotoday @Uromigos @cdanicas @drenriquegrande @koshkin85 https://t.co/HOSSnl6TBj (Twitter) - Sep 12, 2022
- ||||| Clinical: Lenvatinib and pembro in non-clear cell (n=82) (mainly papillary RCC) looks impressive with RR =53% ( for papillary) . Maybe the combinations are better than historical controls for single agent VEGF TKIs. Randomised trials are hard to do, ipi/nivo vs sunitinib awaited #ESMO22 (Twitter) - Sep 12, 2022
- |||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Impressive ORR approaching 50% in renal cell carcinoma with variant histologies with combination of lenvatinib and pembrolizumab and no new toxicity signals presented by @AlbigesL Continue to support trials in this space! https://t.co/AQG2DhEQWk @DrChoueiri @lalaniMD (Twitter) - Sep 12, 2022